[1]
|
World Health Organization (2019) Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
|
[2]
|
AASLD/IDSA HCV Guidance Panel, Chung, R.T., Davis, G.L., et al. (2015) Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus. Hepatology, 62, 932-954. https://doi.org/10.1002/hep.27950
|
[3]
|
Irshad, M., Mankotia, D.S. and Irshad, K. (2013) An Insight into the Diagnosis and Pathogenesis of Hepatitis C Virus Infection. World Journal of Gastroenterology, 19, 7896-7909. https://doi.org/10.3748/wjg.v19.i44.7896
|
[4]
|
Rando-Segura, A., Buti, M., Quer, J., et al. (2019) Viral Load Measurements in Individuals with Hepatitis C Virus Infection: On the European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C 2018. Journal of Clinical Microbiology, 58, Article 013709. https://doi.org/10.1128/JCM.01379-19
|
[5]
|
中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版) [J]. 中华传染病杂志, 2023, 41(1): 29-46.
|
[6]
|
Chung, J.W., Choi, H.Y., Ki, M., et al. (2021) Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study. Gut and Liver, 15, 295-306. https://doi.org/10.5009/gnl19387
|
[7]
|
University of Liverpool (2018) HEP Drug Interactions. https://www.hep-druginteractions.org/checker
|
[8]
|
Louie, K.S., St. Laurent, S., Forssen, U.M., et al. (2012) The High Comorbidity Burden of the Hepatitis C Virus Infected Population in the United States. BMC Infectious Diseases, 12, Article No. 86. https://doi.org/10.1186/1471-2334-12-86
|
[9]
|
Hudson, B., Walker, A.J. and Irving, W.L. (2017) Comorbidities and Medications of Patients with Chronic Hepatitis C under Specialist Care in the UK. Journal of Medical Virology, 89, 2158-2164. https://doi.org/10.1002/jmv.24848
|
[10]
|
Ruzicka, D.J., Tetsuka, J., Fujimoto, G., et al. (2018) Comorbidities and Co-Medications in Populations with and without Chronic Hepatitis C Virus Infection in Japan between 2015 and 2016. BMC Infectious Diseases, 18, Article No. 237. https://doi.org/10.1186/s12879-018-3148-z
|
[11]
|
王琴, 饶慧瑛, 于宁, 等. 成人慢性丙型肝炎合并疾病及用药现状分析[J]. 中华肝脏病杂志, 2018, 26(3): 225-232.
|
[12]
|
Shi, W., Cai, L., Lu, L., et al. (2012) Design of Highly Potent HIV Fusion Inhibitors Based on Artificial Peptide Sequences. Chemical Communications, 48, 11579-11581. https://doi.org/10.1039/c2cc35973a
|
[13]
|
Chong, H., Wu, X., Su, Y., et al. (2016) Development of Potent and Long-Acting HIV-1 Fusion Inhibitors. AIDS, 30, 1187-1196. https://doi.org/10.1097/QAD.0000000000001073
|
[14]
|
Park, J.S., Saraf, N. and Dieterich, D.T. (2006) HBV plus HCV, HCV plus HIV, HBV plus HIV. Current Gastroenterology Reports, 8, 67-74. https://doi.org/10.1007/s11894-006-0066-9
|
[15]
|
Lascar, RM., Lopes, AR., Gilson, RJ., et al. (2005) Effect of HIV Infection and Antiretroviral Therapy on Hepatitis B Virus (HBV)-Specific T Cell Responses in Patients Who Have Resolved HBV Infection. Infectious Diseases, 191, 1169-1179. https://doi.org/10.1086/428502
|
[16]
|
Goeser, F., Glässner, A., Kokordelis, P., et al. (2016) HIV Mono-Infection Is Associated with an Impaired Anti-Hepatitis C Virus Activity of Natural Killer Cells. AIDS, 30, 355-363.
|
[17]
|
Hyun, C.B. and Coyle, W.J. (2004) Hepatocellular Carcinoma in a Patient with Human Immunodeficiency Virus and Hepatitis B Virus Coinfection: An Emerging Problem? Southern Medical Journal, 97, 401-407. https://doi.org/10.1097/01.SMJ.0000072356.46523.29
|
[18]
|
Chew, K.W. and Bhattacharya, D. (2016) Virologic and Immunologic Aspects of HIV-Hepatitis C Virus Coinfection. AIDS, 30, 2395-2404. https://doi.org/10.1097/QAD.0000000000001203
|
[19]
|
杨玉杰, 陆明, 朱垚. 高尿酸血症流行病学调查进展[J]. 保健医学研究与实践, 2023, 20(3): 173-177.
|
[20]
|
Jang, T.Y., Yeh, M.L., Huang, C.I., et al. (2018) Association of Hyperuricemia with Disease Severity in Chronic Hepatitis C Patients. The Public Library of Science, 13, e0207043. https://doi.org/10.1371/journal.pone.0207043
|
[21]
|
Degasperi, E., Galmozzi, E., Pelusi, S., et al. (2020) Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients with Cirrhotic HCV Treated with DAAs. Hepatology, 72, 1912-1923. https://doi.org/10.1002/hep.31500
|
[22]
|
Cuadros, D.F., Miller, F.D.W., Nagelkerke, N., et al. (2015) Association between HCV Infection and Diabetes Type 2 in Egypt: Is It Time to Split Up? Annals of Epidemiology, 25, 918-923. https://doi.org/10.1016/j.annepidem.2015.09.005
|
[23]
|
Niccum, B.A., Stine, J.G., Wynter, J.A., et al. (2020) Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes. Clinical Diabetes, 38, 40-46. https://doi.org/10.2337/cd18-0112
|
[24]
|
Wong, A.H., Sie, J., Chen, A., et al. (2020) Glycemic Control after Initiating Direct-Acting Antiviral Agents in Patients with Hepatitis C Virus and Type 2 Diabetes Mellitus Using the United States Integrated Healthcare System. Journal of Research in Pharmacy Practice, 9, 16-23. https://doi.org/10.4103/jrpp.JRPP_19_110
|
[25]
|
Shih, Y.F. and Liu, C.J. (2020) Hepatitis C Virus and Hepatitis B Virus Co-Infection. Viruses, 12, Article 741.
|
[26]
|
刘淼, 陈华锋, 李梦华. 丙肝患者的甲状腺激素及相关抗体水平的研究[J]. 中国冶金工业医学杂志, 2016, 33(2): 242-243.
|
[27]
|
Maasoumy, B., Port, K., Calle Serrano, B., et al. (2013) The Clinical Significance of Drug-Drug Interactions in the Era of Direct-Acting Anti-Viral Agents against Chronic Hepatitis C. Alimentary Pharmacology & Therapeutics, 38, 1365-1372. https://doi.org/10.1111/apt.12523
|
[28]
|
Höner zu Siederdissen, C., Maasoumy, B., Marra, F., et al. (2016) Drug-Drug Interactions with Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clinical Infectious Diseases, 62, 561-567. https://doi.org/10.1093/cid/civ973
|
[29]
|
Kondili, L.A., Gaeta, G.B., Ieluzzi, D., et al. (2018) Real-Life Data on Potential Drug-Drug Interactions in Patients with Chronic Hepatitis C Viral Infection Undergoing Antiviral Therapy with Interferon-Free DAAs in the PITER Cohort Study. PLOS ONE 13, e0172159. https://doi.org/10.1371/journal.pone.0172159
|